



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



AT₂ Agonist C21 Item No. 33758

CAS Registry No.: 477775-14-7
Formal Name: N-[[3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfonyl]-carbamic acid, butyl ester
Synonym: Compound 21
MF: C₂₃H₂₉N₃O₄S₂
FW: 475.6
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AT₂ agonist C21 is supplied as a solid. A stock solution may be made by dissolving the AT₂ agonist C21 in the solvent of choice, which should be purged with an inert gas. AT₂ agonist C21 is soluble in the organic solvent DMSO.

Description

AT₂ agonist C21 is an agonist of the angiotensin II type 2 (AT₂) receptor.¹ It selectively binds to the AT₂ receptor over the AT₁ receptor (K_{i,s} = 0.4 and >10 μM, respectively). AT₂ agonist C21 (0.1 μM) induces neurite outgrowth in NG 108-15 cells. It reduces mean arterial blood pressure in anaesthetized spontaneously hypertensive rats (SHRs) when administered at a dose of 0.05 mg/kg. AT₂ agonist C21 (0.03 mg/kg) reduces right ventricle hypertrophy and fibrosis, as well as lung interstitial and perivascular fibrosis, in a rat model of pulmonary hypertension induced by monocrotaline (MCT; Item No. 16666).² It increases survival and reduces neurological deficits in a mouse model of cerebral ischemia induced by middle cerebral artery occlusion (MCAO) when administered at the same dose.³

References

1. Wan, Y., Wallinder, C., Plouffe, B., *et al.* Design, synthesis, and biological evaluation of the first selective nonpeptide AT₂ receptor agonist. *J. Med. Chem.* **47(24)**, 5995-6008 (2004).
2. Bruce, E., Shenoy, V., Rathinasabapathy, A., *et al.* Selective activation of angiotensin AT₂ receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. *Br. J. Pharmacol.* **172(9)**, 2219-2231 (2004).
3. Schwengel, K., Namsolleck, P., Lucht, K., *et al.* Angiotensin AT₂-receptor stimulation improves survival and neurological outcome after experimental stroke in mice. *J. Mol. Med. (Berl.)* **94(8)**, 957-966 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/22/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM